Michils A, Lambert J P, Yernault J C, Fabry V, Gossart B, Duchateau J
Chest Department, Erasme University Hospital, Brussels, Belguim.
Cancer. 1996 Feb 15;77(4):657-64. doi: 10.1002/(sici)1097-0142(19960215)77:4<657::aid-cncr11>3.0.co;2-#.
Investigating the humoral immune response to mucosal antigens in patients with lung cancer, we have documented a preferential immunoglobulin G (IgG) binding to cryptic epitopes unmasked by the proteolysis of bovine beta-lactoglobulin (BLG). In contrast, IgG from healthy controls and patients with chronic bronchitis (COPD) bind preferentially to continuous epitopes presented on both native (n) and denaturated (d) forms of this antigen. The present study further characterized the differences in the epitope profiles recognized on BLG.
The capacity of individual sera from 65 lung cancer patients, tested before and after cancer removal for the patients with early stage lung carcinoma, 65 healthy controls, and 52 patients with COPD, to prevent the binding of pooled IgG fractions from each population as well as murine monoclonal antibodies (MoAb), specific for BLG, to solid phase bound antigen was evaluated in enzyme-linked immunoadsorbent assay using streptavidin-biotin technology. Some of these experiments were also performed with sera from 42 patients diagnosed with other cancers.
Compared with control sera and sera from patients with other solid tumors, lung cancer patient sera showed distinct capacities to prevent the binding of murine MoAb as well as human pooled IgG fractions to n- and d-BLG. The inhibition capacities of lung cancer sera changed as soon as five weeks after cancer removal.
The results indicate that the difference in epitope specificity exhibited by lung cancer sera is not restricted to cryptic epitopes, but also affects continuous and discontinuous epitopes, accessible only on the native antigen. A high level of binding discrimination between antibodies from the study populations is also observed at the level of the epitope. This deviation in the epitope specificity of antibodies changes soon after cancer removal, suggesting a tumor-dependent disturbance. Also documented in the Dermatophagoides pteronyssinus model, it opens the way to a new class of paraneoplastic immune markers for this malignancy, with, at first glance, a high specificity level.
在研究肺癌患者对黏膜抗原的体液免疫反应时,我们记录到免疫球蛋白G(IgG)优先结合牛β-乳球蛋白(BLG)经蛋白水解后暴露的隐蔽表位。相比之下,健康对照者和慢性支气管炎(COPD)患者的IgG优先结合该抗原天然(n)和变性(d)形式上呈现的连续表位。本研究进一步表征了在BLG上识别的表位谱差异。
采用链霉亲和素-生物素技术,通过酶联免疫吸附测定法评估65例肺癌患者(早期肺癌患者在癌症切除前后进行检测)、65例健康对照者和52例COPD患者的个体血清阻止各群体混合IgG组分以及针对BLG的鼠单克隆抗体(MoAb)与固相结合抗原结合的能力。其中一些实验也使用了42例被诊断为其他癌症患者的血清进行。
与对照血清和其他实体瘤患者的血清相比,肺癌患者血清在阻止鼠MoAb以及人混合IgG组分与n-BLG和d-BLG结合方面表现出明显的能力。肺癌血清的抑制能力在癌症切除后仅五周就发生了变化。
结果表明,肺癌血清表现出的表位特异性差异不仅限于隐蔽表位,还影响仅在天然抗原上可及的连续和不连续表位。在表位水平上也观察到研究群体抗体之间的高度结合区分。癌症切除后不久,抗体表位特异性的这种偏差就发生了变化,提示存在肿瘤依赖性干扰。在屋尘螨模型中也有记录,这为这种恶性肿瘤开辟了一类新的副肿瘤免疫标志物的道路,乍一看具有很高的特异性水平。